RPL41A Antibody

What is RPL41 and why is it significant in cancer research?

RPL41 is a basic (positively charged) peptide that forms part of the 60S ribosomal large subunit. It consists of just 25 amino acids (MRAKWRKKRMRRLKRKRRKMRQRSK), making it one of the smallest ribosomal proteins. Its significance in cancer research stems from observations that RPL41 down-regulation is associated with malignant transformation. Studies have detected RPL41 deletion in 59% of tumor cell lines and down-regulation in 75% of primary breast cancers, suggesting it plays a tumor suppressor role . Beyond its ribosomal function, RPL41 interacts with cytoskeleton components and affects microtubule stability, which may explain its role in preventing malignant transformation .

What are the known protein interactions of RPL41?

RPL41 has been shown to interact with multiple cellular components through various experimental approaches. Mass spectrometry analyses have identified interactions with several cytoskeleton components, including:

• Tubulin β and γ isoforms

• Myosin IIA

• The beta subunit of protein kinase CKII (Casein Kinase II)

These interactions have been confirmed through Western blot analysis of both cellular lysates and in vitro-expressed proteins . Notably, RPL41 stimulates phosphorylation of DNA topoisomerase II alpha by CKII, suggesting a regulatory role in DNA topology . Additionally, direct binding to polymerized tubulins has been demonstrated through in vitro assays, providing evidence for RPL41's role in microtubule stabilization .

How can RPL41 expression levels be detected in tissue samples?

RPL41 expression can be detected using several complementary approaches:

• Immunohistochemistry (IHC): Using RPL41-specific antibodies to visualize protein expression in fixed tissue sections. Commercial antibodies are available with optimized protocols for IHC applications at dilutions of 1:50-1:200 .

• Western blotting: For quantitative assessment of RPL41 protein levels in tissue lysates. Typical working dilutions for commercial antibodies range from 1:1000-1:3000 .

• Real-time quantitative reverse transcription-PCR (RT-qPCR): For measuring RPL41 mRNA levels, as has been done in studies of primary breast cancers showing 75% down-regulation .

• Fluorescence in situ hybridization (FISH): Particularly useful for detecting RPL41 gene deletions, as demonstrated in studies of tumor cell lines where 59% showed deletions .

Each method provides different information - protein localization (IHC), protein quantity (Western blot), mRNA expression (RT-qPCR), or gene copy number (FISH) - and should be selected based on your specific research question.

What controls should be included when using RPL41 antibodies?

When conducting experiments with RPL41 antibodies, several controls are essential to ensure reliable and interpretable results:

• Positive controls: Include samples known to express RPL41, such as normal tissue samples or cell lines with confirmed RPL41 expression.

• Negative controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG for polyclonal rabbit antibodies)

  • RPL41-depleted samples (cells treated with RPL41-specific siRNA as described in the literature )

• Loading controls: For Western blotting, include housekeeping proteins such as β-actin, GAPDH, or other ribosomal proteins not expected to change under your experimental conditions.

• Peptide competition assay: Pre-incubation of the RPL41 antibody with the immunizing peptide should abolish specific staining, confirming antibody specificity .

• Validation across multiple techniques: Confirm findings using complementary approaches such as immunoblotting, immunohistochemistry, and mRNA quantification.

How does RPL41 depletion affect cellular phenotypes and what methods best capture these changes?

RPL41 depletion induces multiple cellular phenotypes that can be captured through various methodologies:

• Transformation assays: RPL41 down-regulation leads to anchorage-independent growth in soft agar assays, a hallmark of malignant transformation. This can be quantified by counting colony numbers and measuring colony size .

• Mitotic abnormalities: Cells with RPL41 knock-down exhibit:

  • Abnormal spindle formation

  • Frequent cytokinesis failure

  • Polynuclear cell formation

These can be visualized using immunofluorescence microscopy with antibodies against α-tubulin to highlight spindle structure, combined with DAPI staining for nuclear visualization .

• Centrosome integrity assessment: RPL41-depleted interphase cells show premature centrosome splitting, which can be detected using centrosome markers such as γ-tubulin antibodies .

• In vivo tumorigenicity: Xenograft models with RPL41-depleted cells show increased tumor growth in mice, which can be measured by tumor volume and weight over time .

• Microtubule stability assays: Cells with altered RPL41 expression show differential sensitivity to microtubule-disrupting agents like nocodazole. This can be assessed through tubulin polymerization assays and monitoring α-tubulin acetylation levels by Western blotting .

What experimental approaches can resolve contradictory findings about RPL41 function?

When faced with contradictory findings regarding RPL41 function, several experimental approaches can help resolve discrepancies:

• Cell type-specific analyses: RPL41 may function differently across cell types. Comparative studies across multiple cell lines can identify cell-specific effects.

• Rescue experiments: Re-introducing RPL41 expression in depleted cells should reverse the observed phenotypes if they are specifically due to RPL41 loss.

• Domain mapping: Creating truncated or mutated versions of RPL41 can help identify which regions of this small peptide are responsible for specific functions.

• Temporal analyses: Using inducible expression or depletion systems to study the immediate versus long-term effects of RPL41 alteration.

• Context-dependent studies: Investigating RPL41 function under various cellular stresses or cell cycle phases may reveal condition-specific roles.

• Separation of functions: Distinguishing between RPL41's ribosomal and extra-ribosomal functions using ribosome profiling and polysome fractionation alongside cytoskeleton interaction studies .

• Multi-omics approaches: Combining proteomics, transcriptomics, and metabolomics to gain a comprehensive understanding of RPL41's impact on cellular physiology.

How can researchers distinguish between RPL41's ribosomal and extra-ribosomal functions?

Distinguishing between RPL41's canonical ribosomal role and its extra-ribosomal functions requires specialized experimental approaches:

• Subcellular fractionation: Separate nuclear, cytoplasmic, ribosomal, and cytoskeletal fractions to determine RPL41 distribution across cellular compartments. Detect using RPL41 antibodies via Western blotting .

• Proximity labeling: Use BioID or APEX2 fused to RPL41 to identify proximal proteins in living cells, helping to distinguish ribosomal from cytoskeletal interaction networks.

• Ribosome profiling: Compare translational efficiency in normal versus RPL41-depleted cells to assess impact on ribosomal function.

• Structure-function studies: Generate RPL41 mutants that maintain either ribosomal incorporation or cytoskeletal binding, but not both, to parse the contributions of each function.

• Dynamic localization studies: Track GFP-RPL41 localization during different cell cycle phases, particularly during mitosis when its association with microtubules appears functionally significant .

• Direct binding assays: Use in vitro systems with purified components to test direct interactions between RPL41 and cytoskeletal elements like polymerized tubulins, as demonstrated in the literature .

• Selective depletion: Deplete RPL41 from either ribosomes or cytoskeleton specifically through targeted approaches and assess resulting phenotypes.

What methodological considerations are important when studying RPL41's role in microtubule stabilization?

When investigating RPL41's role in microtubule stabilization, several methodological considerations are crucial:

• Purification of synthetic RPL41 peptide: Due to its small size (25 amino acids), RPL41 can be chemically synthesized and HPLC-purified to >95% purity for use in direct binding studies .

• Microtubule polymerization assays:

  • Pre-clear synthetic RPL41 peptide and tubulin solutions by centrifugation to remove aggregates

  • Add GTP (1mM) and paclitaxel (20 μM) to tubulin solutions for polymerization

  • Incubate polymerized tubulin with RPL41 peptide at specific ratios (e.g., 50 μg tubulin to 10 μg RPL41)

  • Use sucrose cushion centrifugation to separate bound from unbound components

• Cellular tubulin stability assessments:

  • Monitor resistance to nocodazole-induced depolymerization in cells overexpressing GFP-RPL41

  • Assess α-tubulin acetylation levels, which correlate with microtubule stability, following RPL41 treatment or manipulation

• G2/M cell cycle analysis: Since RPL41 induces G2/M arrest, flow cytometry can quantify cell cycle distribution following RPL41 manipulation .

• Live-cell imaging: To observe dynamic effects of RPL41 on microtubule behavior in real-time.

• Concentration considerations: Test a range of RPL41 concentrations (typically 100-500 ng/ml) to establish dose-response relationships .

What technical challenges exist in detecting endogenous RPL41 and how can they be overcome?

Detecting endogenous RPL41 presents several technical challenges due to its unique properties:

How can RPL41 antibodies be optimized for different experimental applications?

Optimizing RPL41 antibodies for different applications requires specific adjustments:

• Western Blotting:

  • Working dilution: 1:1000-3000 as recommended for commercial antibodies

  • Detection system: Enhanced chemiluminescence or fluorescent secondary antibodies

  • Blocking conditions: 5% non-fat milk or BSA in TBST

  • Sample preparation: Include phosphatase inhibitors if studying RPL41's relationship with kinases like CKII

• Immunohistochemistry:

  • Dilution: 1:50-1:200 as recommended

  • Antigen retrieval: Test both heat-induced (citrate buffer) and enzymatic methods

  • Detection system: Amplification systems like tyramide signal amplification may improve sensitivity

  • Counterstaining: Hematoxylin provides good nuclear contrast

• Immunofluorescence:

  • Fixation method: Compare paraformaldehyde (structure preservation) versus methanol (better for microtubule visualization)

  • Permeabilization: Titrate detergent concentration to balance antibody access with antigen preservation

  • Co-staining: Combine with cytoskeletal markers (α/β/γ-tubulin) to study colocalization

• Immunoprecipitation:

  • Pre-clearing: Essential to reduce background

  • Antibody amount: Typically 2-5 μg per mg of total protein

  • Buffer considerations: Include RNase treatment if RNA-binding is not being studied

• ELISA:

  • Antibody dilution: 1:20000-1:40000 for peptide ELISA as recommended

  • Standard curve: Use synthetic RPL41 peptide

  • Detection limits: Establish sensitivity range

What protocols can effectively measure RPL41-tubulin interactions in research settings?

Several protocols can effectively measure RPL41-tubulin interactions:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells in non-denaturing buffer (NTEN: 0.5% NP40, 1 mM EDTA, 20 mM Tris, pH 7.4, and 200 mM NaCl)

  • Pre-clear lysates with protein A/G beads

  • Immunoprecipitate with anti-RPL41 antibody

  • Detect co-precipitated tubulins by Western blot

• GST pull-down assays:

  • Express GST-RPL41 in bacterial systems

  • Purify using glutathione-agarose beads

  • Incubate with cell lysates or in vitro translated tubulins

  • Wash stringently (6× with NTEN buffer)

  • Elute and analyze bound proteins by SDS-PAGE

• Direct binding assay with purified components:

  • Centrifuge synthetic RPL41 and tubulin solutions (14,000 rpm, 30 min, 4°C)

  • Polymerize tubulins with GTP and paclitaxel

  • Incubate with RPL41 peptide

  • Separate through sucrose cushion centrifugation

  • Analyze supernatant and pellet fractions

• Surface Plasmon Resonance (SPR):

  • Immobilize synthetic RPL41 peptide on sensor chip

  • Flow purified tubulin at various concentrations

  • Measure association and dissociation kinetics

  • Calculate binding affinity constants

• Fluorescence microscopy colocalization:

  • Transfect cells with GFP-RPL41

  • Immunostain for tubulins

  • Perform deconvolution or confocal microscopy

  • Quantify colocalization using Pearson's or Mander's coefficients

How should researchers design experiments to assess RPL41's tumor suppressor function?

When designing experiments to assess RPL41's tumor suppressor function, consider these methodological approaches:

• Expression analysis in clinical samples:

  • Compare RPL41 expression levels in matched tumor/normal tissue pairs using RT-qPCR

  • Perform FISH analysis to detect RPL41 gene deletions in tumor samples

  • Use RPL41 antibodies for IHC on tissue microarrays to correlate expression with clinical outcomes

• In vitro transformation assays:

  • Establish stable cell lines with RPL41 knockdown using specific siRNAs

  • Perform soft agar colony formation assays to assess anchorage-independent growth

  • Measure proliferation rates in low serum conditions

  • Assess migration and invasion using transwell assays

• Genetic manipulation studies:

  • Create cell lines with inducible RPL41 expression

  • Perform rescue experiments in RPL41-depleted cells

  • Use CRISPR/Cas9 to generate RPL41 knockout cell lines

• In vivo tumorigenicity:

  • Inject RPL41-depleted cells into immunocompromised mice

  • Monitor tumor growth over time

  • Perform limiting dilution assays to assess tumor-initiating capacity

  • Analyze tumor histology and marker expression

• Mechanism investigation:

  • Examine changes in centrosome integrity and mitotic spindle formation

  • Assess chromosome segregation errors

  • Quantify polynuclear cell formation

  • Investigate the interaction between RPL41 and known tumor suppressors

• Signaling pathway analysis:

  • Determine if RPL41 affects key oncogenic pathways

  • Investigate its impact on CKII-mediated phosphorylation of DNA topoisomerase II alpha

What are the most reliable methods for quantifying RPL41-mediated effects on microtubule dynamics?

To quantify RPL41-mediated effects on microtubule dynamics reliably, researchers should consider these methods:

• Live-cell imaging of microtubule plus-end tracking proteins (+TIPs):

  • Transfect cells with fluorescently tagged EB1 or CLIP-170

  • Track growth rates, catastrophe frequencies, and rescue events

  • Compare between RPL41-normal and RPL41-depleted conditions

• Microtubule regrowth assays:

  • Depolymerize microtubules with cold treatment or nocodazole

  • Allow regrowth at 37°C

  • Fix cells at various time points

  • Quantify microtubule nucleation and polymerization rates

• Fluorescence Recovery After Photobleaching (FRAP):

  • Express fluorescently labeled tubulin

  • Photobleach defined regions

  • Measure fluorescence recovery rate to determine microtubule turnover

  • Compare between cells with normal and altered RPL41 levels

• Post-translational modification analysis:

  • Quantify acetylated α-tubulin levels by Western blotting

  • Measure detyrosinated tubulin (a marker of stable microtubules)

  • Assess polyglutamylation and polyglycylation states

• In vitro tubulin polymerization assays:

  • Monitor turbidity at 340 nm over time in the presence/absence of synthetic RPL41

  • Calculate polymerization rates and plateau levels

  • Test at various concentrations of RPL41 peptide

• Drug sensitivity assays:

  • Compare sensitivity to microtubule-stabilizing (paclitaxel) and destabilizing (nocodazole) drugs

  • Generate dose-response curves in RPL41-normal versus RPL41-depleted cells

What controls and validation steps are essential when publishing research involving RPL41 antibodies?

When publishing research involving RPL41 antibodies, include these essential controls and validation steps:

• Antibody validation:

  • Demonstrate specificity using Western blotting on multiple cell types

  • Perform peptide competition assays to confirm specificity

  • Include RPL41-depleted samples as negative controls

  • Provide complete antibody information (manufacturer, catalog number, lot, dilution)

• Reproducibility controls:

  • Replicate key experiments with different antibody lots

  • Use multiple antibodies targeting different epitopes when possible

  • Perform biological and technical replicates with appropriate statistical analysis

• Method validation:

  • Include positive controls known to express RPL41

  • Demonstrate dynamic range of detection methods

  • Provide detailed protocols including blocking conditions, incubation times, etc.

• Functional validation:

  • Confirm phenotypes observed with antibody-based detection using genetic approaches

  • Perform rescue experiments to establish specificity

  • Validate protein interactions using reciprocal co-immunoprecipitation

• Data presentation:

  • Show representative full blots/gels including molecular weight markers

  • Present quantitative data with appropriate statistical analysis

  • Include dot plots or box plots showing individual data points rather than just averages

• Technical considerations:

  • Describe how the small size of RPL41 (3 kDa) was addressed in SDS-PAGE

  • Detail any specialized protocols needed for this unusually small, basic protein

  • Explain methods used to distinguish RPL41 from other small ribosomal proteins

Research Applications Table

What emerging technologies might enhance our understanding of RPL41 function?

Several emerging technologies show promise for advancing our understanding of RPL41 function:

• Cryo-electron microscopy: To visualize RPL41 interactions with ribosomes and cytoskeletal components at near-atomic resolution, potentially revealing structural mechanisms underlying its dual functionality.

• Proximity labeling techniques: BioID or APEX2 fused to RPL41 could identify proximal proteins in living cells, expanding our understanding of its interaction network beyond the currently known partners .

• Single-molecule imaging: To track individual RPL41 molecules in living cells, providing insights into its dynamic localization and interaction with microtubules during different cell cycle phases.

• CRISPR-based genomic screens: To identify synthetic lethal interactions with RPL41 depletion, potentially revealing new therapeutic targets for cancers with RPL41 deletion.

• Proteomics of post-translational modifications: To investigate how modifications of RPL41 might regulate its extra-ribosomal functions, particularly during cell cycle progression.

• Ribosome profiling in RPL41-depleted cells: To comprehensively assess how RPL41 loss affects translation of specific mRNAs, potentially revealing mechanisms connecting ribosome function to cytoskeletal regulation.

• Patient-derived organoids: To evaluate the effects of RPL41 manipulation in more physiologically relevant 3D culture systems that better recapitulate tumor microenvironments.